Glucagon constant-rate infusion: A novel strategy for the management of hyperinsulinemic-hypoglycemic crisis in the dog

Journal of the American Animal Hospital Association

Volumn 36, Issue 1, 2000, Pages 27-32

  Fischer, Julie R ^a   Smith, Stephanie A ^a   Harkin, Kenneth R ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; INSULIN; PREDNISONE; STREPTOZOCIN;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DOG; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN HYPOGLYCEMIA; NONHUMAN; TREATMENT OUTCOME;

BOVINAE; CANIS FAMILIARIS;

EID: 0033986738     PISSN: 05872871     EISSN: None     Source Type: Journal    
DOI: 10.5326/15473317-36-1-27     Document Type: Article

References (17)

1. Feldman EC, Nelson RW. Canine and feline endocrinology and reproduction. 2nd ed. Philadelphia: WB Saunders, 1996:422-41.
2. Sieber FE, Traystman RJ. Special issues: glucose and the brain. Crit Care Med 1992;20(1):104-14.
3. Kruth SA, Feldman EC, Kennedy PC. Insulin-secreting islet cell tumors: establishing a diagnosis and the clinical course for 25 dogs. J Am Vet Med Assoc 1982;181(1):54-8.
4. Hadley ME. Endocrinology, 4th ed. Upper Saddle River: Prentice-Hall, 1996:231-49.
5. Goodman HM. Basic medical endocrinology. 2nd ed. New York: Raven Press, 1994:115-34.
6. Meleo K. Management of insulinoma patients with refractory hypoglycemia. Probl Vet Med 1990;2(4):602-9.
7. Robben JH, Visser-Wisselaar HA, Rutteman GR, et al. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas. J Nucl Med 1997;38:1036-42.
8. Lothrop CD. Medical treatment of neuroendocrine tumors of the gastroenteropancreatic system with somatostatin. In: Kirk RW, ed. Current veterinary therapy X. Philadelphia: WB Saunders, 1989:1020-4.
9. Simpson KW, Stepien RL, Elwood CM, Boswood A, Vaillant CR. Evaluation of the long-acting somatoslalin analogue octreotide in the management of insulinoma in three dogs. J Sm Anim Pract 1995;36(161):161-5.
10. Feldman EC, Nelson RW. Canine and feline endocrinology and reproduction. 2nd ed. Philadelphia: WB Saunders, 1996:38-66.
11. Leifer CE, Peterson ME, Matus RE. Insulin-secreting tumor: diagnosis and medical and surgical management in 55 dogs. J Am Vet Med Assoc 1986;188(1):60-4.
12. Siegel EG, Creutzfeld W. Effect of low concentrations of glucagon on insulin release and cyclic AMP content in isolated rat islets. Metabolism 1987;36(10):953-7.
13. Guyton AC, Hall JE. Textbook of medical physiology. 9th ed. Philadelphia: WB Saunders, 1996:978-9.
14. Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 1998;82(8):1585-92.
15. Giacca A, Fisher SJ, McCall RH, Shi ZQ, Vranic M. Direct and indirect effects of insulin in suppressing glucose production in depancreatized dogs: role of glucagon. Endocrinology 1997;138(3):199-1007.
16. Fenner WR. Diseases of the brain. In: Ettinger SJ, ed. Textbook of veterinary internal medicine. 4th ed. Philadelphia: WB Saunders, 1995:614-5.
17. Koopmans SJ, Ohman L, Haywood JR, Mandarino LJ, DeFronzo RA. Seven days of euglycemic hyperinsulinism induces insulin resistance for glucose metabolism bin not hypertension, elevated catecholamine levels, or increased sodium retention in conscious normal rats. Diabetes 1997;46(10):1572-8.